BMO Capital Markets has raised its price target for Eli Lilly to $1,100 from $930, maintaining an Outperform rating. This significant increase is attributed to the company's expanding market leadership in the obesity treatment sector, where its drugs Mounjaro and Zepbound are gaining prescription share over competitors' products. Analysts at BMO cited recent prescription trends that demonstrate Eli Lilly capturing more of the market, solidifying what they term an "obesity duopoly" that is increasingly favoring Lilly. This positive outlook follows the company's strong third-quarter earnings report and recent announcements of major investments in manufacturing capacity.